Dr. Jianzhong Cao 曹建忠
Chief Physician, Associate Professor
Department of Radiation Oncology, Shanxi Cancer Hospital, Taiyuan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Comprehensive treatment centered on radiotherapy for head and neck tumors, and thoracic tumors including lung cancer, esophageal cancer, and thymoma.
Dr. Cao holds a medical doctorate and serves as a master’s supervisor. Trained at Bethune Medical University, Tsinghua University Peking Union Medical College, and Cancer Hospital of the Chinese Academy of Medical Sciences under Professors Luo Jingwei and Wang Luhua. Recognized as an academic leader in Shanxi Province.
Professional roles
- Vice Chair, Radiotherapy Professional Committee, China Medical Education Association
- Vice Chair, National Geriatric Oncology Radiotherapy Professional Committee
- Member, Radiotherapy Professional Committee, Chinese Medical Association
- Young Committee Member, Radiotherapy Professional Committee, China Anti-Cancer Association
Name order: in Chinese the family name comes first (Cao Jianzhong). Papers usually list the name as Jianzhong Cao or Cao J.
Selected publications
81 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Oncoimmunology, 2026 (senior author): Reshaping immunotherapy sequencing strategy: equivalent survival with induction plus consolidation vs. consolidation-only strategy in unresectable stage III NSCLC. PubMed 42141789
- Front Immunol, 2026 (senior author): Risk stratification model based on estimated dose of radiation to immune cells and radiotherapy-related nadir lymphocyte count for predicting the efficacy of consolidation immunotherapy in stage III non-small cell lung cancer. PubMed 42495622
- Cancer Treat Res Commun, 2026 (senior author): Clinical efficacy and safety of an overall strategy of immunotherapy combined with chemoradiotherapy for limited-stage small cell lung cancer (including induction ± consolidation ± second-line immunotherapy): A propensity score matching study based on real-world data. PubMed 42250432
- Front Microbiol, 2025 (senior author): Microbiota-mediated modulation of radiosensitivity: mechanisms and therapeutic prospects of oral and gut microbiota, metabolites, and probiotics. PubMed 41450947
- BMC Cancer, 2024 (senior author): Development of a novel nomogram for patients with SCLC and comparison with other models. PubMed 39390375
- Cancer Biomark, 2024 (senior author): Serum aspartate aminotransferase, a novel potential biomarker of prognosis in extranodal natural killer/T cell lymphoma, nasal type. PubMed 38108343
- Cancer Biomark, 2024 (senior author): Impact of the peripheral blood inflammatory indices and modified nomogram-revised risk index on survival of Extranodal Nasal-Type Natural Killer/T-Cell lymphoma. PubMed 37522199
- BMC Cancer, 2022 (senior author): Prognostic ability of lung immune prognostic index in limited-stage small cell lung cancer. PubMed 36447193
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion